Genprex, Inc. Gains 64.35%
Wed, Jan 22, 2020 at 05:30 PM
Genprex, Inc. (GNPX:NASDAQ) soared at $1.89, representing a gain of 64.3%. On Tue 21 Jan 20, GNPX:NASDAQ hit a New 2-Week High of $1.15. The stock appeared on our News Catalysts scanner on Wed 22 Jan 20 at 12:01 PM in the 'BIOTECH' category. From Mon 30 Dec 19, the stock recorded 42.86% Up Days and 26.67% Green Days
The stock spiked on Tue 21 Jan 20 at $1.74 with a volume of 53M+.
About Genprex, Inc. (GNPX:NASDAQ)
Genprex Inc is a clinical stage gene therapy company. It develops therapies that carry cancer-fighting genes. Its initial product candidate is Oncoprex.
Top 10 Gainers:
- Genprex, Inc. (GNPX:NASDAQ), 64.35%
- Concert Pharmaceuticals, Inc. (CNCE:NASDAQ), 33.03%
- Tetraphase Pharmaceuticals, Inc. (TTPH:NASDAQ), 29.73%
- Genius Brands International, Inc. (GNUS:NASDAQ), 27.12%
- One Stop Systems, Inc. (OSS:NASDAQ), 25.85%
- Inuvo, Inc. (INUV:NYSEMKT), 23.28%
- Baudax Bio, Inc. (BXRX:NASDAQ), 21.16%
- Express, Inc. (EXPR:NYSE), 20.72%
- AgEagle Aerial Systems, Inc. (UAVS:NYSEMKT), 20.2%
- Applied Genetic Technologies Corporation (AGTC:NASDAQ), 19.52%